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We are building a new disposable manufacturing system to support the development and manufacturing of mAb 
and mAb-related products. We have made choices that are different than many others in the field of continuous 
and integrated processing. These choices avoid many misperceptions about continuous processing, are 
consistent with a staged approach to implementation,  and facilitate manufacturing in either large-scale 
disposable or stainless manufacturing facilities.  
 
We have avoided the use of long-term steady-state perfusion. This mode of perfusion suffers from long 
development times, long manufacturing duration, extended Process Performance Qualification, large media 
consumption and perceived concerns about product quality variability and contamination.  
The system uses a short duration (<15 days) non-steady state perfusion with perfusion rates as low as 0.3 
bioreactor volumes per day.  On-line UPLC is used to monitor product titer and quality.  As a consequence of 
non-steady state perfusion operation, the integrated downstream is capable of handling day to day variability of 
0.5g/L/day to 4g/L/day.  The downstream avoids the use of SMB or PCC; rather, it integrates two batch 
chromatographic steps, a continuous virus inactivation step, and avoids in-process pooling. The product is 
stored after the second chromatography step for the duration of the batch. When the batch is complete, the 
pooled product is batched through a virus reduction filter and UFDF to make the bulk drug substance. Running 
these last two processes on the entire product pool at once allows an easy definition of a batch, without worry 
about pooling drug substance with different product quality profiles.  
 
The result is an integrated, semi-continuous manufacturing process that mitigates many of the concerns felt by 
the batch-processing community. 
